On Friday, Western Digital Corp (NASDAQ:WDC)’s shares declined -2.18% to $80.02.
WD®, a Western Digital® (WDC) company, and world leader in storage solutions, recently declared the expansion of its award-winning WD Red Pro hard drive line with the release of 5 TB and 6 TB capacities. The WD Red Pro family is ideal for NAS (network attached storage) systems having up to 16 drive bays and serving businesses with more expansive storage needs than the standard WD Red drives.
Shipping now, WD Red Pro 5 and 6 TB drives leverage an improved design and 128 MB cache to deliver data transfer rates of 214 megabytes per second (MB/s). WD’s NASware™ 3.0 features technology promoting data protection, high NAS performance and reliable integration.
WD Red Pro 6 TB hard drives feature the following:
Up to 16 Bay Shock Protection – Equipped with a multi- axis shock sensor, the drive automatically detects subtle shock events and, together with dynamic fly height technology, adjusts each read-write function to compensate and protect the data, further protecting the drive in large 1- to 16-bay NAS environments.
NASware 3.0 – Exclusive advanced firmware enables seamless integration, robust data protection and optimal performance for systems operating in the demanding NAS environment.
Vibration Protection – Hardware vibration compensation technology monitors the drive to correct both linear and rotational vibration in real time, further increasing drive reliability and enabling high performance in higher vibration systems caused from drive to drive vibration in addition to from the high speed fans used to cool the larger systems.
Western Digital Corporation, together with its auxiliaries, engages in the development, manufacture, sale, and provision of data storage solutions that enable consumers, businesses, governments, and other organizations to create, manage, experience, and preserve digital content worldwide. The company’s product portfolio comprises hard disk drives (HDDs), solid-state drives (SSDs), direct attached storage solutions, personal cloud network attached storage solutions, and public and private cloud data center storage solutions.
Paychex, Inc. (NASDAQ:PAYX)’s shares dropped -0.87% to $44.31.
The Paychex | IHS Small Business Jobs Index reduced 0.17 percent from July to August, bringing the national index to 100.48. Little movement in recent months gave way to August’s decline. The index was down 0.51 percent from August 2014. The East North Central continued as the top-performing regional index despite a slight decrease month over month. Wisconsin surpassed Washington to lead among states tracked by the index, while Dallas has continued success as the top-ranked metro area for 11 straight months.
“The Paychex | IHS Small Business Jobs Index declined 0.17 percent in August. Nevertheless, small business job gains continue at a pace 0.48 percent faster than in our base period ten years ago,” said James Diffley, chief regional economist at IHS.
Paychex, Inc. provides payroll, human resource, insurance, and benefits outsourcing solutions for small to medium-sized businesses in the United States and Germany. The company offers payroll processing services that comprise the calculation, preparation, and delivery of employee payroll checks; production of internal accounting records and administration reports; preparation of federal, state, and local payroll tax returns; and collection and remittance of clients payroll obligations.
At the end of Friday’s trade, American Capital Ltd. (NASDAQ:ACAS)‘s shares dipped -0.36% to $13.65.
American Capital, Ltd. (ACAS) (“American Capital” or the “Company”) declared recently that an associate, ACAS CLO 2015-2, Ltd. (“ACAS CLO 2015-2”), has closed on the sale of $510 million of collateralized loan obligation (“CLO”) bonds. The transaction was arranged by Wells Fargo Securities, LLC. ACAS CLO 2015-2 is externally managed by American Capital CLO Administration, LLC, which is a partner of American Capital Asset Administration, LLC, a wholly owned portfolio company of American Capital, for an annual base administration fee of 0.5% and up to 20% incentive fees, subject to performance hurdles.
ACAS CLO 2015-2 has invested the proceeds of the bonds primarily in broadly syndicated senior secured floating rate loans purchased in the primary and secondary markets. American Capital Asset Administration, LLC manages about $4.3 billion of loan and loan-related assets in eight American Capital CLOs, in the equity of about 65 third-party CLOs and American Capital Senior Floating, Ltd. (ACSF) as of June 30, 2015.
The bonds sold by ACAS CLO 2015-2 comprised of tranches rated Aaa(sf) through Ba3(sf) by Moody’s, AAA(sf) tranches rated by Fitch and non‑rated subordinated notes.
American Capital, Ltd. is a private equity and venture capital firm specializing in administration and employee buyouts, subordinated debt, leveraged finance, mezzanine, acquisition, recapitalization, middle market, early venture, mature, industry consolidation, and growth capital investments.
Array Biopharma Inc (NASDAQ:ARRY), ended its Friday’s trading session with -2.60% loss, and closed at $5.62.
Array BioPharma Inc. (ARRY) stated results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
Ron Squarer, Chief Executive Officer of Array, noted, “Binimetinib and encorafenib, two innovative oncology products in Phase 3, are on track for regulatory submissions in 2016. Additional data shared over the summer in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate the value of these programs by showing the potential for differentiation contrast to other approaches. Binimetinib and encorafenib have accelerated our path to commercialization and provide us with opportunities to test these broadly active products across a number of indications.”
Array ended the quarter with $185.1 million in cash, cash equivalents, marketable securities and accounts receivable. Accounts receivable as of June 30, 2015 primarily comprises of current receivables predictable to be repaid by Novartis within three months. Revenue for the fourth quarter of fiscal 2015 was $12.3 million, contrast to $6.0 million for the same period last year. The $6.3 million enhance in revenue from the preceding period was primarily due to $5.7 million in reimbursable research and development expenses from Novartis. Cost of partnered programs for the fourth quarter of fiscal 2015 was $7.0 million, contrast to $11.4 million for the same period last year. Research and development expense was $18.6 million, contrast to $14.5 million in the same preceding year period. The enhance in research and development expense and corresponding decrease in cost of partnered programs is related to binimetinib and encorafenib being recently classified in research and development for the last three months of the fiscal year, rather than in the cost of partnered programs. Net loss for the fourth quarter was $12.7 million, or ($0.09) per share (diluted), and was $28.2 million, or ($0.22) per share (diluted), for the same period in fiscal 2014.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
